Literature DB >> 22397722

CCL2 and CXCL2 enhance survival of primary chronic lymphocytic leukemia cells in vitro.

Melinda Burgess1, Catherine Cheung, Lynne Chambers, Karunya Ravindranath, Gunjeet Minhas, Louise Knop, Peter Mollee, Nigel A J McMillan, Devinder Gill.   

Abstract

Chronic lymphocytic leukemia (CLL) is predominantly a disease of accumulation rather than rapid proliferation. To date, no cell lines exist, as CLL cells undergo rapid apoptosis when cultured in vitro, suggesting that a favorable in vivo microenvironment is required. To identify survival signals we cultured primary CLL peripheral blood mononuclear cells (PBMCs) at high density, which has previously been shown to dramatically improve survival. Using antibody arrays we measured the level of 42 cytokines in culture supernatants and showed that inerleukin-6 (IL-6), IL-8, CXCL2 and CCL2 were highly up-regulated in culture. This is the first report to describe a role for CCL2 and CXCL2 in CLL cell survival. Importantly, CXCL2, IL-6 and IL-8 were significantly up-regulated in primary patient plasma. The addition of either CXCL2 or CCL2 enhanced CLL cell survival, while antibodies blocking these chemokines reduced survival. Co-culture of CLL cells and PBMC accessory cells separated by transwells provided a similar degree of survival protection compared to normal culture, whereas CLL cells cultured alone died rapidly. Interestingly, CCL2 and CXCL2 appeared to be produced by CLL cells but only when co-cultured with accessory cells. Thus, we speculate that accessory cells release soluble factors that promote the production of these pro-survival chemokines from CLL cells and physical interactions are not required. Our data support the concept that the CLL microenvironment is critical, and suggests that soluble factors are more important than physical interactions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22397722     DOI: 10.3109/10428194.2012.672735

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  25 in total

1.  Lenalidomide interferes with tumor-promoting properties of nurse-like cells in chronic lymphocytic leukemia.

Authors:  Stefania Fiorcari; Silvia Martinelli; Jenny Bulgarelli; Valentina Audrito; Patrizia Zucchini; Elisabetta Colaci; Leonardo Potenza; Franco Narni; Mario Luppi; Silvia Deaglio; Roberto Marasca; Rossana Maffei
Journal:  Haematologica       Date:  2014-11-14       Impact factor: 9.941

2.  The prognostic significance of serum and cerebrospinal fluid MMP-9, CCL2 and sVCAM-1 in leukemia CNS metastasis.

Authors:  Meng-Ya Si; Zhi-Cheng Fan; Ya-Zhen Li; Xiao-Lan Chang; Qing-Dong Xie; Xiao-Yang Jiao
Journal:  J Neurooncol       Date:  2015-01-30       Impact factor: 4.130

Review 3.  In Vitro and In Vivo Models of CLL-T Cell Interactions: Implications for Drug Testing.

Authors:  Eva Hoferkova; Sona Kadakova; Marek Mraz
Journal:  Cancers (Basel)       Date:  2022-06-23       Impact factor: 6.575

4.  Loss of miR-532-5p in vitro promotes cell proliferation and metastasis by influencing CXCL2 expression in HCC.

Authors:  Xiaofei Song; Zie Wang; Yan Jin; Yong Wang; Wenbing Duan
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

5.  IL-4 rescues surface IgM expression in chronic lymphocytic leukemia.

Authors:  Benchang Guo; Lu Zhang; Nicholas Chiorazzi; Thomas L Rothstein
Journal:  Blood       Date:  2016-05-25       Impact factor: 22.113

6.  CCL2 in chronic lymphocytic leukemia: a macro in microenvironment?

Authors:  Varsha Gandhi; Kumudha Balakrishnan
Journal:  Leuk Lymphoma       Date:  2012-05-21

7.  Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.

Authors:  Carsten U Niemann; Sarah E M Herman; Irina Maric; Julio Gomez-Rodriguez; Angelique Biancotto; Betty Y Chang; Sabrina Martyr; Maryalice Stetler-Stevenson; Constance M Yuan; Katherine R Calvo; Raul C Braylan; Janet Valdez; Yuh Shan Lee; Deanna H Wong; Jade Jones; Clare Sun; Gerald E Marti; Mohammed Z H Farooqui; Adrian Wiestner
Journal:  Clin Cancer Res       Date:  2015-12-09       Impact factor: 12.531

8.  HIF-1α regulates the interaction of chronic lymphocytic leukemia cells with the tumor microenvironment.

Authors:  Roberta Valsecchi; Nadia Coltella; Daniela Belloni; Manfredi Ponente; Elisa Ten Hacken; Cristina Scielzo; Lydia Scarfò; Maria Teresa Sabrina Bertilaccio; Paola Brambilla; Elisa Lenti; Filippo Martinelli Boneschi; Andrea Brendolan; Elisabetta Ferrero; Marina Ferrarini; Paolo Ghia; Giovanni Tonon; Maurilio Ponzoni; Federico Caligaris-Cappio; Rosa Bernardi
Journal:  Blood       Date:  2016-01-29       Impact factor: 22.113

9.  Candidate markers that associate with chemotherapy resistance in breast cancer through the study on Taxotere-induced damage to tumor microenvironment and gene expression profiling of carcinoma-associated fibroblasts (CAFs).

Authors:  Guohua Rong; Hua Kang; Yajun Wang; Tao Hai; Haichen Sun
Journal:  PLoS One       Date:  2013-08-08       Impact factor: 3.240

10.  A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor.

Authors:  Russell T Burke; Sarah Meadows; Marc M Loriaux; Kevin S Currie; Scott A Mitchell; Patricia Maciejewski; Astrid S Clarke; Julie A Dipaolo; Brian J Druker; Brian J Lannutti; Stephen E Spurgeon
Journal:  Oncotarget       Date:  2014-02-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.